Hadassah University Medical Center - Israel
AUTHOR PROFILE
SCOPUS
EARLY ACADEMIC PURSUITS
Dr. Nathalie Asherie began her academic journey with a Bachelor of Science in Biotechnology Engineering from ORT Braude College in Karmiel, Israel, graduating cum laude in 2000. She then pursued a Master’s degree in Microbiology at the Hebrew University, Hadassah Medical School, Jerusalem, from 2002 to 2005. Her thesis focused on the involvement of the CD44 molecule in Type 1 diabetes of non-obese diabetic (NOD) mice. She continued her education at the same institution, earning a Ph.D. in Immunology, also with honors, and receiving the Excellence Prize for her Ph.D. thesis in 2012. Her doctoral research delved into the role of CD44 in Type 1 diabetes, identifying a redundant molecule, RHAMM, that supports the migration of inflammatory cells, and examining CD44’s role in β-cell demise.
PROFESSIONAL ENDEAVORS
Dr. Asherie's professional career began with a research associate position at Omrix Biopharmaceuticals, where she contributed to the development of life-saving products derived from human plasma. She then interned at Alomone Labs, focusing on polyclonal antibody design and production. Her extensive industry experience provided a solid foundation for her later roles in academia and clinical research.
Dr. Asherie's research focuses on finding applicative solutions to immune disorders, including autoimmunity, immune deficiency, and cancer. Her significant contributions include the optimization of anti-BCMA CAR-T cells, process development, Medicine and Health Sciences and CAR humanization. Her work on the anti-BCMA CAR-T based treatment for MM and AL is particularly noteworthy, having enrolled and treated nearly 80 patients. Her innovative research has been published extensively, highlighting her role in advancing cellular therapies and immunological treatments.
IMPACT AND INFLUENCE
Dr. Asherie’s impact is evident in her numerous publications and the successful clinical trials she has led. Her work has garnered recognition in the scientific community, evidenced by awards such as the First Best Abstract Award at the 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies in 2022 and the Excellence Prize for her Ph.D. thesis. Her contributions to the field of immunology and cellular therapy have influenced current practices and opened new avenues for treatment.
ACADEMIC CITES
Dr. Asherie’s research has been widely cited in the scientific literature, reflecting her influence in the field. Key publications include her work on the anti-BCMA CAR-T cells published in Haematologica and the Journal of Clinical Oncology, Medicine and Health Sciences which have contributed significantly to the understanding and treatment of multiple myeloma and other immune-related disorders. Her research on the molecular mechanisms involving miR-103 in glucocorticoid-induced apoptosis of hemopoietic tumor cells has also been influential.
LEGACY AND FUTURE CONTRIBUTIONS
Dr. Asherie’s legacy is marked by her pioneering research and successful implementation of advanced cellular therapies. Her work on CAR-T cell therapy for cancer treatment represents a significant advancement in the field. Moving forward, she aims to continue her research in immunology, focusing on developing novel treatments for immune disorders and enhancing the efficacy of existing therapies. Her commitment to training new personnel and her ongoing contributions to clinical trials ensure that her impact will extend well into the future.
NOTABLE PUBLICATIONS
Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed 2024(1)
Clonal Myeloid Dysplasia Following CAR T-Cell Therapy: Chicken or the Egg? 2023(3)
Early lymphocyte collection for anti-CD19 CART production improves T-cell fitness in patients with relapsed/refractory 2023(4)
Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis 2022(11)